Mark A. Lemmon

Mark Lemmon FRS
Mark Lemmon at the Royal Society admissions day in London in 2016
Fields	Growth factor receptor signaling Cancer Biology
Institutions	University of Pennsylvania Yale University
Alma mater	University of Oxford Yale University
Thesis	Specific interactions between transmembrane alpha-helices: Their role in the oligomerization of integral membrane proteins (1993)
Doctoral advisor	Donald Engelman
Website www.med.upenn.edu/lemmonlab/ medicine.yale.edu/pharm/people/mark_lemmon.profile

Mark Andrew Lemmon FRS, an English-born biochemist, is the David A. Sackler Professor of Pharmacology at Yale University where he co-directs the Cancer Biology Institute with Joseph Schlessinger.

Lemmon was born in Norfolk, England in 1964. He was educated first at Norwich School, and then at Hertford College, Oxford, from which he graduated with a first class Bachelor of Arts degree in Biochemistry in 1988. He completed his PhD at Yale University as a Howard Hughes Medical Institute Predoctoral Fellow supervised by Donald Engelman for research on the oligomerization of transmembrane α-helices. Following his PhD, Lemmon was a postdoctoral researcher and fellow of the Damon Runyon Cancer Research Foundation at New York University in the laboratory of Joseph Schlessinger.

Following his postdoctoral studies, Lemmon was recruited to the Department of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine, where he gained tenure in 2001 and became Departmental Chair in 2008. He remains an Adjunct Professor of Biochemistry and Biophysics at University of Pennsylvania.